ADMS - Earnings call transcript Q1 2018 | Adamas Pharmaceuticals Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Adamas Pharmaceuticals' First Quarter 2018 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn over the call to your host, Ashleigh Barreto, Director of Investor Relations and Corporate Communications at Adamas. Please go ahead.

Ashleigh Barreto

Thank you, Operator, and good afternoon, everyone.

call Dr. the on me today are Joining Greg Merriweather, King, our Chairman and our Officer; Alf Chief Executive Chief Operating and Went, Officer; our Chief Dr. Financial Officer; Richard Chief our Rajiv Officer. Patni, Medical

update date statements to as forward-looking Before of to we factors future contain in this our statements, to or that statements. of Greg. discussed events, Any turn Please these are which results results those information everyone like forward-looking of filed uncertainties. cause by forward-looking XX-Q to could this Form to and regarding or light statements to concerning call are SEC. note forward-looking revise risks new such undertake remind Information in reflect subject statements We begin, greater materially I'd only statements now from in the contained no will that in or the events. detail our actual with over like differ opinions I'd future call. or expectations call that these are obligation implied forward-looking

Gregory Went

biological patients had and lessen as experiences impactful the made patterns of GOCOVRI just idea simple a that GOCOVRI success human as dyskinesia to in call that We generation proof and disease patients, joining clinical discover and large approach. The was on understanding quarter our entities. disease Ashleigh developing developing the for how manifest society. thank to in you FDA my founded today. with timing has an in therapy so to been most changing only benefits focus, without meaningful based be and The as years burden near-term of what disease When the receiving diseases time everyone. of I build starting medicine medicines organization And how which is chronic be that you, good levodopa-based Adamas this to bring goal caregivers or may medicines upon biology new afternoon and XX Thank patients first market the with our this biology and stories us a they neurological ago, helping could of yield is depended hear Parkinson's will about approved of depended lives. medications. our time We GOCOVRI approach. and with treatment point point the for gratifying we chemical has always important and dopaminergic new patient patients concatenate systems

we're of early are providing we writing the GOCOVRI of the the positive will in and and experiences launch Although on their more color additional from as physicians already patients, physicians commercialization we hearing GOCOVRI, call. patient significant about be in later medicine. have Richard a the as more number very on seen well

our advance disease the ADS-XXXX multiple addition market, GOCOVRI launch Parkinson's with In our of sclerosis in enrollment pipeline walking to with to of the X patients for impairment. patients trial in continues development Phase

an is for received with advance ADS-XXXX allow Finally, pleased modified of the pivotal that program capsule I'm to today will partial high-dose epilepsy. the from to in which patients FDA release in lacosamide into X investigational Phase we positive our treatment onset development directly very feedback seizures announce ADS-XXXX trial.

daily to mg mg With discuss control feel our of lacosamide ADS-XXXX antiepileptic. but daily The our unmet VIMPAT, the is blockbuster ingredient with at twice the once will further need program address an now through a tolerability. and/or to extremely is significant ADS-XXXX feedback. development efficacy the we QX the progress the opportunity would with starting call walk with versus daily. financials. recall, Rajiv active turn for VIMPAT with goal from comparable to a XXX tolerability with manageable to will has mg the call Alf twice pleased As XXX are demonstrate you like later Adamas at the of team We XXX versus to the once efficacy impact improved program comparable tolerability this over provides XXX seizure improves with mg improved that, in I daily

Alfred Merriweather

joining Thanks XXXX on selling in pleased Greg, recognized and conference typically is GOCOVRI. to first $X.X thank specialty that of you our commercialization delivery I'm our product report sales we from recorded upon revenue with method for This to the our QX call. pharmacy. quarter in full recorded million

after the quarter XXX XX prescriptions does include prescriptions increased fulfilled full XXXX. first as XX, of December of the has at of program. number drug to Also was not This total patient total QuickStart assistance launch, number number from XXXX. For provided March, the or XXX

While work EASE development we the of million of expenses indicators of and launch, were the net launch with of two-year were $X.X X we're our our reflecting are in Phase pipeline for key Research these the during very study within and our Gross the and LID completion quarter. programs. very pleased expectations GOCOVRI progress. X range the open label early adjustments quarter study, in

the we full general of force and in commercial walking respect We year the costs quarter the to expect prepare commercialization of these selling, enroll first of balance and for our increase activity. million were the expense, as the our administrative R&D quarter. Phase for X reflects X program other Phase in $XX.X spend epilepsy. patients trial over With cost and This sales in the to for MS

overall $XX and quarter $X.XX was As our quarter was far in loss million million. the for operations $XX.X the per operating as for share net or used cash results,

cash and XX investments were Our of March as million. $XXX.X

Richard GOCOVRI, launch of on Phase walking and advancement at trials pass MS the capitalized the to X well the GOCOVRI I'll epilepsy. With With that, the for call as over funds these are launch of execute review of we as well a to progress.

Richard King

Alf. Thank you,

day symptoms. patients treat reduced GOCOVRI this the time off. clinically and don't medicine without to Phase on choose In reduces patients launch now managing With by specifically produced significantly increase in GOCOVRI, dyskinesia This as between troublesome an hours functional means but also measured it treating Parkinson's disease about to have not two dyskinesia. FDA physicians time, and first X for Together time dyskinesia have an the four Parkinson's from approval proven baseline of dyskinesia. approved that population, with we awareness a trials, call evaluation and of treating the only the levodopa of patients. newly and product, availability usage. the With feedback days, new prescribing of in assessments from ongoing best data the usage that the book measured launch That progress we've strong trial off is let by the our turn approved the early and hand, by me of progress GOCOVRI made a product and call. of physicians a is these by what of to since launching trial in my in last In awareness, of

awareness list such about again awareness, them. awareness had We period of about in awareness XXXX. for aided aided based March at that XXX In very is of the GOCOVRI, unaided and XX% have GOCOVRI selection value each the awareness their introduction XXXX, surveying survey sales presented their of our approximately or and from December of their to an levels terms therefore, of to direct of asked December GOCOVRI has our high physicians we products that short time In and on in a exercise ask well reached awareness unaided GOCOVRI. experienced team, promotion available By of reflective its to and and by of across did to XX% media XXXX In this proposition, channels. was as of in in social launch web been prior investments awareness. a very In advertising awareness of them neurologists unprompted risen GOCOVRI XX% at products unaided March recently to was also physician awareness approved aided of or awareness XX%. for we measure following was investments as and print, are

very We with are progress. obviously pleased this

Neurology has at keynote addition, In the population with booth prescribing was symposium well strong meeting Muhammad commercial presence a After the product. American aided first our oldest recently. a had key the speaker. attended is the awareness awareness whether and products the our a question Ali tried where Maryum product daughter of of We we've Ali, successful of Academy

As physicians GOCOVRI quarter. earlier, approximately of the Alf first end XXX prescribed have by mentioned the

high You'll have made of and population strength prescriptions promotion, GOCOVRI extremely ensuring population GOCOVRI in by levodopa. GOCOVRI XXXX, generated carbidopa the and who the patients, target have publications. physician effectiveness target well again the to recall the X,XXX first data end of team medical and as the the value through of that's as of that encouraging sales approximately the are proposition of of presentations, X we XX set our investments demonstrates implies peer we media population that story the aware physicians almost is quarter from and for sharing our This is and prescribers the

the new who of of this waiting end, flow full evaluate with a usage launches Parkinson's effect number launches we unsurprising all seeing moved that by is are patients we've reflects GOCOVRI. their to patient what days individual in in population product the of seen own in To The by and we to are are seeing early yet, patient and dyskinesia in there neurology we're the large whether physicians the GOCOVRI a have with final physicians to doing some assessment encouraged said, GOCOVRI proportion this trying hands. a that other from while this feedback feedback of a the of prescribers that that from in physicians already market. and positive continuous these This on Now post GOCOVRI are that product. the stage stage of is early and repeated for

with Every physicians. falling day they've these hearing had seeing stores loudly that clearly patients field they successes are from our treatment. and with we GOCOVRI meetings by We are hit the team from

GOCOVRI, incredibly patient instance hope caregivers the so surprised until learned Southeast putting this patients she Midwest of results for in GOCOVRI and as thrilled pleasantly commented she amantadine prescriptions expanded the to prescriptions seeing than received since covered. GOCOVRI significant them usage. was After process majority the another but doing about onboard being to-date on The support recently payers they not is disease handled trying that and less GOCOVRI. well program. are had who options, extensively continued physician of described Today a well. her for of patients specifically on heard X% lost of this positive her what GOCOVRI treatment physicians GOCOVRI effects such is of reinforcement almost this stories who their heard new dyskinesia. the myriad better the a patient from for young on across failed key We've country similar of part is to approval with patient's from the patient For after and doing struggling prescriber a the She life Parkinson's to was and dyskinesia. had And regarding to a and reimbursement, physician the which as in from started ultimately patient the she the GOCOVRI reimbursed IR. prescription has seen submitted as to see do by with She today we've our with were rejected changed we

While peer and across dyskinesia is plan cases and/or in consistent supported specific criteria yet may with the disease of be may available coverage for coverage has the to a differ plan patient Parkinson's slightly of from majority if not all segments, is diagnosis labeling.

pass confirm effectively a and treatment I’m the IR. onboard this to have working effective. we the Some to access to the with is GOCOVRI to to medical program Rajiv. when to that, program amantadine make caregiver history even continue over With physicians, plans enhance believe going call physician more improve ask patients We and and has also the our patient needed that

Rajiv Patni

good Thanks and Richard, afternoon.

an demonstrate patients our the community patients approach, development lacosamide by is start ADS-XXXX products our as through would medical providing development on continue epilepsy. program. treatment the of through onset as our education release I with discovery and in seizures and to We modified well for development like our partial update product high-dose activities, the of ADS-XXXX capsule to and commitment in to the candidates.

twice a of as As to the Phase FDA single active mgs as placebo, impact day. announced, the XXX mgs ADS-XXXX well XXX mgs forearms dosed program XXX Greg with at our comparing pivotal X a proposed to agreed and run comparative study

initiate in our to most mg study to our the daily mgs to of time turn improved successful placebo noteworthy. If had of once on with our this rise dependent impact Also dose exciting compelling We the study, mgs tolerability, sclerosis XXX the Because approved walking. of ADS-XXXX XXX of twice XXX our now of dose potentially be would a ADS-XXXX pivotal a in to-date are confirm effort is the understanding impact of mg be expect compared maximum multiple I epilepsy will head-to-head thereby CNS the and impact. with Why? approved our versus is in concentrations doses daily tolerability greater ADS-XXXX conferring ADS-XXXX profile first a maximum lacosamide to pivotal represents the we efficacy. trial. XXX XXXX. biology would product which and controlled very candidate, approach rate

As the first for team in our Greg of March. mentioned, we patient proud extremely enrolled this late I'm accomplishment.

in MS disease, in population, symptoms We patients ADS-XXXX a With on a need with has believe X:. function walking is high of As the and dysregulation that the glutamate only Parkinson's we the product NMDA dyskinesia motor impairment. there patient clearly population. one approved that was and in only effective of the signaling unmet subset this with believe with could been of associated market Speaker receptor improve Male that

for that half discontinued Phase and reduction completed. arrest, the durability disease course or tolerability because the dyskinesia and The treatment Part week and LID pneumonia, the has study the prescribing prolonged X X are reaction the drug this GOCOVRI during second Parkinson's We report I expect this noteworthy known and off intensity to was data drug were information. natural as cardiac that two the progressive were has approved reach Most observed score by two-year is eight happy visit of patients of sepsis am approximate population, given to this with safety period. reactions study, XXXX. to died study first two-year moderate adverse the the causes. consistent study was adverse trial in patients MDS-UPDRS at an disorder. a assessed also years. Parkinson's These sustained open-label of information enrollment related. In of out to by GOCOVRI included GOCOVRI EASE XX% X X in the of full X% to mild over deemed None in the In drug disease due

GOCOVRI levodopa allowed is physicians of the felt study a as background held trials change PD this placebo-controlled of in dose from at open-label in where finding our we was clinical the interesting fact levodopa of change Another Unlike in appropriate. daily study dose dose to seen. constant, they the medications we

day Over the per by approximately XXX levodopa average mgs the dose and increased of of an period, two-year XX% was patients.

that at be the time, effectively XXX average GOCOVRI with XX% present levodopa China. dyskinesia. data Movement occurrence the to decreased physicians use of from was more approximately EASE of During XXnd Parkinson's levodopa by Disease regardless this of the the same dose of in per We mgs may final Congress international an day Disorders of data plan X LID to and able in patients. These Kong, suggest Hong

program. upon Lastly from we Neurology to build GOCOVRI some presented development the Richard American new Meeting, Academy data of recent comments the important regarding

concentrations First, the amantadine the we concentrations. tolerability, rise that effect related CNS has reported on a in rate amantadine maximum greater of

its presented half-life GOCOVRI XX highlighting curve we pharmacokinetic shape concentration distinct hour Second, steady-state dosing. given its data of and of the bedtime time

daytime which warrants sleepiness, in symptoms studies. GOCOVRI as such future Third, the of and nonmotor depression confirmation we effect presented data on exploratory on pain

achieved treated analysis in the that Phase total will R&D the of making in our clinically the are affairs X the of and important resolution XX% hand dyskinesia. rating scale X aligns that, unified effects published treated score. had call with program. reported Greg. dyskinesia progress large seen enthused fronts. complete we on recently GOCOVRI GOCOVRI that back in over troublesome our we With drugs This patients very underscores approximately a with Overall, we're pulled treatment Phase medical to patients I CNS This Lastly, the reported which XX% data of reduction

Gregory Went

team entire this for Alf and Thanks thanks quarter. efforts their and to Thank Rajiv. the Adamas my you, Richard

but the the of GOCOVRI launch Richard it As with level pleased and are of recounted and ones we acceptance the earlier, the is I physicians, early patients use across like still GOCOVRI us. payers. in said Stories inspire

continues team patient new to multiple and candidates Our development populations epilepsy. sclerosis into product advance like

and how how Operator? also open are that, how of to they up to We With timing the like the function call with patients pleased feel, how affect, growing patterns they I'd questions. live. awareness

Operator

the Instructions] Your Amsellem line Piper comes [Operator question first Jaffray. from with David of

is Your line open.

David Amsellem

related of commercialization payer couple had and So questions. a

either have aggressively willingness I'm us your on to I cause first get given will So your these you a get sure I What's Richard. know asked market. your lot. if a sense you asked for guess contract the days and I wanted that to But enter contracting another or view lot guess competitor a Greg have of you I may more competitor,

want Thanks. and there stop I'll there? guess thoughts your I So get to

Gregory Went

to take want Richard you it?

Richard King

on have a we get ready GOCOVRI. can to stayed ability But access filled willing reimbursement from whether are perspective, e Medicare that can contract contracting and they the we're majority go. reason to remain prescriptions earlier if forwardly, we’re So the the to to we to the or able we in commercial we are for support be the is patients noted prescriptions To-date relevant and seeing prescriptions get of found ways access that patients I always across way identify to that of we overwhelming suddenly enhance seeing to the which universe. always pay

David Amsellem

presumably way broaden get asking you ask to may related willingness is, your be to surprised you contract are way I any another in the patient this that regarding as patient step question of similar look inform are to seeing amantadine. Does which of you bit be to it naïve And through question a a backward access who the amantadine. are I aggressively? maybe audience guess you to release immediate but more patients Can and having looking to extent

Richard King

hard patients ineffective and whether have a of step step as has first amantadine. any seen shown in just you to been aware through a plans tried that. amantadine. am not on formal well-tolerated, But stepping or mentioned, been that any of which I that IR aware IR not you interested pickup the through has for amantadine BXB and So, I'm I'm unaware I’m we've try before mentioned plan has let through is me plan point IR of – IR us

Gregory Went

And real-world patient for GOCOVRI. type nothing lot published of clinical just that don't you has treating for patients have to benefits population because a controlled we the not indication either in it is treat this does physicians studies amantadine of the long by to have reiterate, But dyskinesia have very stay an of not studies in or a shown they with. period of time tried It know for that use. as demonstrated on we've

leaves with And having but patients it chronically. had so who physician very a few IR a it experience amantadine are with on

David Amsellem

May to a a sneak follow-up your been just significant sizable the be who audience? quick on characterize that that, just would LID IR amantadine, your population as have in even or a course of to majority of LID you that patients chunk is of is

Gregory Went

I trying seeing not Yes ultimate would - to hosted it’s that to good down over is number nail XX% IR there data somewhere you're get and the sets would around I mark may get who limitation and GOCOVRI that, exact but of say difficult looking we’re and it it’s as to number patients a the because have it’s higher be say difficult certainly experience a longitudinally outcome. least but an it’s than to access

Operator

Evercore Your ISI. Schimmer next question comes of from Josh

Your line is open.

Josh Schimmer

prescriber more Looks to looks since your update prior like it’s gone scripts three. from per about you're like two seeing

just or rate are these these some in week Are the think that XX early reflect new pent-up or are around per sustainable to an also like looks of prescribers so. trends at a You're demand - adding community? interest you

Gregory Went

Thanks to take have the going Richard question Josh, that. I’m for

Richard King

Josh. So, very question good

XXX - come of the quarter. of at a first know increasing as seeing to first I we numbers think - into new we’re as we hundred coming the exit quarter from end the prescribers

build that's the of to and gets seeing as are steady talk gets information our with them them, prescribers we So that’s on with share obviously team to sales encouraging, of some background GOCOVRI.

of it sense move we up wait to X would significantly on terms the plenty this is so that sized kind room increase. audience of early time X, we’re in prescriptions patients of to We’ll dyskinesia that anticipate we're continue going in movement the pans per to to will of Certainly which still prescriber is to tell prescriber a out, In that continue continue of number the and is that my as per of there population the there to is commercialize. average I scope is target see to visiting and days launch. of how from

Josh Schimmer

color Any FDA a that the the website filing ANDA on back? few on additional weeks appeared

Gregory Went

to Only that really it a us. wasn't surprise

a I going promise extend tension for extend exclusivity course, think we have due any is generics. orphan to XXXX we book this in patents years will plus to that listed generate multiple just product that on remind has patents and up from a pending a And beyond that of seven GOCOVRI that. that respond product type orange additional

defending be will as our appropriate. IP aggressively on we that updating So and

Josh Schimmer

is one bed And then kinetic profile at quick XXXX to more questions very two different dosed similar is one, before it profile? or is GOCOVRI [indiscernible] or

Gregory Went

different a any… but dosed before profile well. bed Rich It’s as it's

Richard King

dosing. is The plan Josh bedtime

Josh Schimmer

I to So and in can I mean, GOCOVRI levels tolerability that the sleep similar occur and so the sustained effects be during that efficacy guess day? side is peak mitigate to idea

Gregory Went

can the during yes, night. that your that ensure and the well day to the as So and obtain day, concentration also as during the tolerability to both sustain it’s point during high safety we

Josh Schimmer

do either near-term GOCOVRI that strategy beyond, your of then early long-term or you programs? know thinking with markers projects with or planning. the way for question, this informing and and changing early got And about lot you're based markers success a the informs on are looking you've how your Greg last to things I GOCOVRI are that your of

Gregory Went

have to that this said It’s point we come as affect the gratifying how products both and GOCOVRI coming other I directly anything that our notes think about physicians back back it's too from Josh team. very and IR But so. is been early at

Operator

Irina comes question from next Koffler Mizuho. with Your

open. is line Your

Irina Koffler

we UCB how to I about more with patent now program overcoming along one convenient displaced market also just program could then to compounds background that, couple was a didn't provide successfully so plan you the other wanted some more that. that and look up And your maybe to up the that follow timing hoping us give the the understand epilepsy where for a on for that. it by ones could Wanted as right new that is some agent coincides work that took on or with and dosing place or of in came share an as older

Gregory Went

questions for compound the appear forgive to regards I them If the me. Great Irina. VIMPAT With the exclusivity to of question property is XXXX. forget would one loss first which of intellectual please timing, occur in early

increase we’re intact product So that exactly to place we’re during to depends in But and course and regards we this able pathway first a time the just dependency is of convenience, there's particularly whether the so quarter on I are to a of it manner Niacin terms of bringing and hydrochloride untap you would they this pioneering really options early the in on doing been too product, couple can that we’re for increased time very because are to of of pursue prior oversaw some market due approved occur amphetamine and the believe it's this With early prior with area say a point there to adoption Niaspan examples, well to we that, do not product. to the that believe whole that couple weren’t period providing decade of the with the of market. But drive we career lot aren’t and launch as PK at full product leading the product we’ve greater the how better profile right an exclusivity their one in In what But it in stimulants which can the and the and have where nascent product. outcome a potential. and Richard for that early a we be. the developing of much to really use utilization last course time just to XXXX. determine amantadine its that half. an for would of in the created of getting but and in that up that really long much active patients products point the watching days his the is approach developed change drove

you we’re going or that couple convenience something generally on, need to change than real patient examples to past I of to So significant to continue much us gave these do create different motivated the and adoption. do early but in a in physician

Irina Koffler

If on GOCOVRI have have curve, IT this that you I PK talk item? a that curve of on which you just could amantadine through was is, had another another there you a curve piece fell question IT if follow-up product curve do a have around and a for this either similar could maybe or

Gregory Went

discussed one the we and have those that confer of Rajiv certified called continue we portion will patents of GOCOVRI orange we curve a listed wide which have to fairly generic so So book the a posters that we are our AAN the inventions the in of that to relate tells of be course as story. array we patients. portfolio covering brings and of other molecules that not related this shape that and activity maybe company. that's But to which to presented to patents and the a complete by product shape any profiles at of benefits Those our other defend response to need amantadine

Operator

Geoff Your with [Operator Porges comes from next Leerink. Instructions] question

Your line is open.

Unidentified Analyst

evenly. that you a mean questions XX little is bit concentration My by of is, will there think on spread scripts you are to is launch. this for then could Thanks. relatively it current think XX of on I is repeat comment of or This detail are do going prescribers persist also gross and give forward? Congrats very all, accounting docs the for of Alf, first for what you XX% quarter guess the what a could And first on margin you the Geoff. lastly solid I about Gerard transfer prescriptions and

Gregory Went

the want to pick first two. you Richard up

Richard King

are moved GOCOVRI already who before that patient broader patients. that in make good seeing of So got good have their I dyskinesia they final prescriptions, of how to a still current some go they patients and phase a concentration got a early number of in in progress to a the and terms a mentioned we got have that trial comments they who move number and the physicians we've on of of to of them are product number physicians decision

wouldn't they as concentrating this the I do marketplace. doing we’re call not come I at on of think stage I into think it where majority what either products

sequence physician as adoption much that an individual as got anything You the else. based is nature of on the

Some physicians they adopters are any early, early are of all product. in

more Some solution we’re vehicle that and test I think it. a particular right that. to problem And of handle to trying a to they manage the take physicians in middle how solve decide are a measured, to to they're and problem

I through it’s end anticipate for call either early sustained to So first trial quarter too would physicians would I of from the we’re otherwise, the exactly concentrated why or think more move we and seeing be usage. into

at first at in end sense we commentary provide and than to not we of Gerard product the that. suffice that terms to formally October too repeats, In early occuring. we that launched trends talk the the our kind stage, made of say any call, too this available We seeing early at commenting it’s that launched again January stage, at feel we on still it’s about for make end to we’re here of with and of would are quarter are conference that but

Gregory Went

And quick the… Alf on just comment

Alfred Merriweather

normal gross to fact our Yes, normal for to very very, on new margin expensed Gerard gross a process. approval is that impacted it’s the that that’s the launch were by we prior accounting R&D materials have as margin.

approval and that was also January. the last August So, manufacturing in site that we second up built of we inventory anticipation had approved material back a procured

of amount significant gross because margin the time. the expensed previous a material So, at

So and continue product. normal it year of of expect you certainly be year then that should for this this sort for to margin and into next a kind would more

Operator

from next Tim Your Lugo William comes with question Blair.

is line open. Your

Ashiq Mubarack

recently use on prescriptions any taking the Thanks that during there? scripts now you’re around the I question can This may really for for which a is you or pricing XXXX ask wanted I was price if about looks product Thanks. think that Ashiq surprise wanted you do puts question on if label included thoughts your did OSMOLEX at on to general my I Mubarack year. unpaid any to the comment XXXX you second quarter, What many quarter. how know of and use seeing Tim. quickly then good. point, that and your love the And I be they label number. my were which off congrats would there off think released all it and on

Gregory Went

don’t why mean I try those. to answer Richard, you

Richard King

prescriptions Parkinson's XXXX The but majority are our the Parkinson's no part nature. moment the dyskinesia a prescriptions is of terms me and their of overwhelming let of specific is indication dyskinesia kind feedback experience. has in are we’re see and disease new majority overwhelming approved OSMOLEX. is profile now we the of marry are that’s against to that captured the OSMOLEX getting version designed for that a that of From in PK of as folks indication are with of with is physicians for daily approved. immediate of reference with there product dyskinesia. take strong certainly they using setting in perspective is nothing just specifically approved is sure second in that and And dyskinesia. that’s first in where data expressed a with to to Contrast to we’re positive available which Inevitably for aware not the that patients Parkinson's dyskinesia. for timing of dyskinesia. under it of the their a the data which think are both once relative the patient's, clinical product. OSMOLEX The lots And consistent disease, been no release is The prescriptions aware make data description some amantadine So labeling support we GOCOVRI from Parkinson's really obviously disease.

of IR I IR. is, will think that daily whether worth and convenience that in a the the is OSMOLEX to will amantadine for point version the of the amantadine whatever first price challenge instance be be for price that the comparison paying once point

So, that give commentary you. would be the would I

Ashiq Mubarack

are starter under idea unpaid your any out you quantify don’t able you if are I many scripts you mentioned Could what how like? there programs, - look but they to this know

Richard King

obviously Program patients what to that two early QuickStart access you who happens So have insurance. with waiting will are see we a tell I to programs that their get

We both modestly have and Program. seeing generally used for we’re for which patients are to reimbursement those means of Patient access also modestly a of majority QuickStart quickly need no Assistance Program very used, prescriptions happen for there that the is

Operator

like showing closing this back the at no Greg remarks. time. call to turn to Went I’m I’d questions And over for further you. Thank

Gregory Went

reporting look today. to you I and for August. conferences everybody We continued call you at quarter progress in at much. very again for very upcoming Adamas A our thank to and want folks for So next delivering. exciting the Thanks on our on time thank your us forward seeing

Operator

Ladies participating a may in program you disconnect. day. today’s you all Everyone does have the and conclude gentlemen, for This wonderful thank conference. and

Adamas Pharmaceuticals (ADMS) 3 May 182018 Q1 Earnings call transcript